Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical ...
Cipla share price had fallen after the company's September quarter results as analysts cut their target price, citing weaker than expected domestic business and challenges in its key products.
Adams said he believed it was unlikely that Kennedy could be appointed to lead a major health agency because he has no medical expertise, it would likely be difficult for him to pass a background ...
Cipla projects a mid-FY26 launch for Advair, while the release of Abraxane is contingent on regulatory clearance of the company's Goa facility. Respiratory drug Albuterol faces intensifying ...
QIAGEN is expanding its portfolio for QIAstat-Dx in North America, with the recent launch of the QIAstat-Dx Analyzer 2.0, FDA clearance of the Gastrointestinal Panel 2 and submission for FDA clearance ...